AMAsim Mushtaq

Asim Mushtaq

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asim Mushtaq has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • A. Anitha

    School of Chemistry and Molecular Biosciences The University of Queensland Cooper Road Brisbane Queensland 4072 Australia

    3 shared publications
  • Li Li

    The University of Queensland

    3 shared publications
  • Lisbeth Grøndahl

    School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Qld 4072, Australia

    3 shared publications
  • Adrian Dinsdale

    Plant Innovation Centre, Australian Government, Department of Agriculture, Fisheries and Forestry (DAFF), Canberra, ACT, 2601, Australia

    1 shared publication
  • Ahmed Saad

    Centre for Crop Health, Institute for Agriculture, Climate and the Environment, University of Southern Queensland, Toowoomba, Queensland, 4350, Australia; Department of Primary Industries and Regional Development, South Perth, WA, 6151, Australia

    1 shared publication
  • Alina Karki

    Centre for Crop Health, Institute for Agriculture, Climate and the Environment, University of Southern Queensland, Toowoomba, Queensland, 4350, Australia

    1 shared publication

Latest Publications

  • Open Access

    Polymeric microneedle patches for rapid DNA extraction and molecular diagnosis of foliar pathogens of mung bean

    by Asim Mushtaq, Barsha Poudel, Alina Karki, Pouria Azarikhah, Ahmed Saad, Adrian Dinsdale, Sonia Fiorito, Noel L. Knight, Zahra Faraji Rad

  • Open Access

    Functionalizing low-value mineral-derived Al2O3 towards cost-effective fire-retardant epoxy composites

    by Yong Guo, Xiaoning Song, Qingshan Yang, Boyou Hou, Asim Mushtaq, Hong Peng, Siqi Huo, Pingan Song


  • Open Access

    Chitosan‐Based Nanoparticles for Twist1 Knockdown in 4T1 Cells

    by Asim Mushtaq, Li Li, Anitha A, Lisbeth Grøndahl

    Bone metastasized breast cancer reduces the quality of life and median survival. Targeted delivery of twist1‐siRNA using nanoparticles (NPs) is a promising strategy to overcome current limitations in treating such metastatic breast cancers. This research evaluates two types of chitosan (CHI)‐based NPs for the delivery of twist1‐siRNA. Alendronate conjugated PEG functionalized chitosan (ALD‐PEG‐CHI) NPs are developed for active targeting while PEG functionalized CHI (mPEG‐CHI) NPs are fabricated for passive targeting. The size of twist1‐siRNA‐loaded NPs is below 70 nm and the zeta potential is near neutral for both types of NPs. Based on gel retardation assay, complete encapsulation of twist1‐siRNA is achieved in both NP systems. The ALD‐PEG‐CHI‐siRNA and mPEG‐CHI‐siRNA NPs display serum protection for 6 and 4 h, respectively, compared to the immediate degradation of naked twist1‐siRNA. The NPs can knockdown twist1 in 4T1 cells as demonstrated through protein expression as well as by phenotypic change in directional cell migration by wound healing assay. Overall, these in vitro results illustrate the potential of the NPs as an effective therapeutic system for bone metastasized breast cancer.


  • Open Access

    Targeted Nanoparticles Based on Alendronate Polyethylene Glycol Conjugated Chitosan for the Delivery of siRNA and Curcumin for Bone Metastasized Breast Cancer Applications

    by Asim Mushtaq, Li Li, Lisbeth Grøndahl, Anitha A

    Bone metastasized breast cancer reduces the quality of life and median survival. Targeted delivery of small interfering RNA (siRNA) and chemotherapeutic drugs using nanoparticles (NPs) is a promising strategy to overcome current limitations in treating these metastatic breast cancers. This research develops alendronate conjugated polyethylene glycol functionalized chitosan (ALD‐PEG‐CHI) NP for the delivery of cell death siRNA (CD‐siRNA) and curcumin (CUR) and explores its targeting ability and in vitro cell cytotoxicity. Polyethylene glycol functionalized CHI (mPEG‐CHI) NPs serve as control. The size of CD‐siRNA loaded NPs is below 100 nm while CUR loaded NPs is below 200 nm, with near neutral zeta potential for all NPs. The CUR encapsulation efficiency (EE) is 70% and 88% for targeted and control NPs, respectively, while complete encapsulation of CD‐siRNA is achieved in both NP systems. The bone targeting ability of CY5‐dsDNA loaded ALD‐PEG‐CHI NPs using hydroxyapatite discs is fivefold compared to control indicating ALD presentation at the targeting NP surface. Delivery of CD‐siRNA loaded NPs and CUR loaded NPs show synergistic and additive growth inhibition effects against MCF‐7 cells by mPEG‐CHI and ALD‐PEG‐CHI NPs, respectively. Overall, these in vitro results illustrate the potential of the targeted NPs as an effective therapeutic system toward bone metastasized breast cancer.


  • Development and in vitro evaluation of a targeted nanotherapeutic system for bone metastasised breast cancer

    by Asim Mushtaq

    The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.

  • Chitosan Nanomedicine in Cancer Therapy: Targeted Delivery and Cellular Uptake

    by Asim Mushtaq, Li Li, Anitha A., Lisbeth Grøndahl

    Nanomedicine has gained much attention for the management and treatment of cancers due to the distinctive physicochemical properties of the drug‐loaded particles. Chitosan's cationic nature is attractive for the development of such particles for drug delivery, transfection, and controlled release. The particle properties can be improved by modification of the polymer or the particle themselves. The physicochemical properties of chitosan particles are analyzed in 126 recent studies, which allows to highlight their impact on passive and active targeted drug delivery, cellular uptake, and tumor growth inhibition (TGI). From 2012 to 2019, out of 40 in vivo studies, only 4 studies are found reporting a reduction in tumor size by using chitosan particles while all other studies reported tumor growth inhibition relative to controls. A total of 23 studies are analyzed for cellular uptake including 12 studies reporting cellular uptake mechanisms. Understanding and exploiting the processes involved in targeted delivery, endocytosis, and exocytosis by controlling the physicochemical properties of chitosan particles are important for the development of safe and efficient nanomedicine. It is concluded based on the recent literature available on chitosan particles that combination therapies can play a pivotal role in transformation of chitosan nanomedicine from bench to bedside.